~~<i id='7293E40587'><strike id='7293E40587'><tt id='7293E40587'><pre id='7293E40587'></pre></tt></strike></i>~~

Home» focus» Wikipedia

Wikipedia

author：Wikipedia 2025-10-04 06:02:04 Page View：218

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Pregnancy discrimination could be enabled by AI
Next article： Heart attack and stroke risk calculators need revising

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Congenital heart disease patients face new threat of heart failure

AdobeWhenJenniferCasewaslivinginLosAngelesinherearly30s,shewashospitalized11times.Shehadbeenbornwith

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

First medicine developed to treat MASH expected to be approved soon

MadrigalCEOBillSiboldsaysthecompanyis"interestedinthepatientswhoaremostinneed."MadrigalPharmaceutica

WSS

Wikipedia

Wikipedia

comprehensive

leisure time

First medicine developed to treat MASH expected to be approved soon